Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553165 | 0.90 | TSHR (0.39) | LMNATSHRSMN1; SMN2TP53MAPT | |
| SCHEMBL21553046 | 0.86 | KMT2A (0.42) | LMNATSHRSMN1; SMN2TP53MAPT | |
| SCHEMBL23258228 | 0.85 | KDM4E (0.37) | TSHRSMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL23258120 | 0.85 | PDE1B (0.41) | HSD17B10LMNASMN1; SMN2TP53MAPT | |
| SCHEMBL21552837 | 0.85 | ALDH1A1 (0.36) | HSD17B10LMNATSHRSMN1; SMN2TP53 | |
| SCHEMBL23258245 | 0.80 | MAPK1 (0.39) | HSD17B10LMNATSHRSMN1; SMN2TP53 | |
| SCHEMBL21553142 | 0.79 | KDM1A (0.47) | — | |
| SCHEMBL23258246 | 0.78 | MAPT (0.36) | TSHRSMN1; SMN2MAPTKMT2AGAA | |
| SCHEMBL21552986 | 0.78 | MAPK1 (0.40) | TSHRSMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL21552980 | 0.76 | CYP11B1 (0.43) | LMNASMN1; SMN2MAPTJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | Imago Biosciences. Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1A, KDM1B, KDM2A | HSD17B10 1947/4885LMNA 1443/4885TSHR 4375/4885 |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | HSD17B10 1762/4885LMNA 1741/4885TSHR 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.